Anticonstipation Drugs

Safety and subtype come before escalation

A stronger laxative is not a substitute for diagnosing obstruction or pelvic floor dysfunction.

First look for severe pain, vomiting, distention, obstipation, bleeding, weight loss, anemia, fever, abrupt change, or a mass; suspected mechanical obstruction requires evaluation rather than oral laxative escalation.

Then review constipating drugs and secondary causes, distinguish chronic idiopathic constipation from IBS-C pain, slow transit, defecatory disorder, and hepatic encephalopathy, and correct reversible contributors.

Use fiber when low intake and hydration are the main problems, PEG or another appropriate osmotic agent for persistent chronic constipation, and prescription secretory or prokinetic therapy when phenotype and prior response justify it.

If outlet symptoms or failed balloon expulsion suggest dyssynergic defecation, pelvic floor biofeedback addresses the mechanism better than stacking more stool-water drugs.

The target can be lumen, epithelium, nerve, muscle, or outlet

An anatomic map prevents a luminal solution from being forced onto an outlet problem.

Bulk and osmotic agents work mainly within the lumen, while secretagogues act at the apical epithelial surface and prokinetics act through enteric neural signaling and colonic motor patterns.

A defecatory disorder sits at the pelvic floor and anal outlet, where soft stool can still fail to pass because coordination rather than water is the limiting step.

Lactulose links colon and liver: bacterial fermentation acidifies colonic contents, favors ammonium trapping, and increases fecal nitrogen elimination in hepatic encephalopathy.

Mechanism names predict both benefit and harm

The same ion or motor pathway that softens stool usually explains the adverse effect.

More luminal water can become diarrhea, dehydration, or electrolyte disturbance; more propulsion can become urgency and cramping.

GC-C agonists increase cyclic GMP and CFTR-mediated chloride and bicarbonate secretion, while NHE3 inhibition reduces sodium absorption from the intestinal lumen.

Lactulose is fermented in the colon, increasing osmolality and acidifying the lumen; in hepatic encephalopathy, lower pH traps diffusible ammonia as ammonium and faster transit increases nitrogen elimination.

If the mechanism leaves more water in the lumen, diarrhea is the predictable overshoot.

Each class pushes a different physiologic lever

Constipation drugs differ by whether they add bulk, retain water, trigger secretion, or propel the colon.

Bulk agents such as psyllium retain water and enlarge stool, while docusate lowers surface tension to let water and lipid penetrate stool; docusate is weaker than many patients assume for established chronic constipation.

Osmotic agents such as polyethylene glycol and lactulose keep water in the lumen; stimulant agents such as bisacodyl and senna promote secretion and motility and are useful for rescue or selected regular use.

Lubiprostone activates type 2 chloride channels, while linaclotide and plecanatide activate epithelial guanylate cyclase-C, increase cyclic GMP, activate CFTR-mediated chloride and bicarbonate secretion, and pull water into the lumen.

Prucalopride is a selective 5-HT4 agonist that stimulates colonic high-amplitude propagating contractions, while tenapanor inhibits apical NHE3 to reduce sodium absorption and increase luminal water in adult IBS-C.

Bulk, water, secretion, and propulsion are four different treatment verbs.

Daily targets expose overtreatment

Frequency should be tied to a therapeutic target rather than to the idea that more bowel movements are always better.

Common chronic idiopathic constipation regimens such as PEG, a GC-C agonist, or prucalopride are generally scheduled once daily, while tenapanor for adult IBS-C is taken twice daily immediately before breakfast and dinner.

For hepatic encephalopathy, lactulose is titrated to a clinical target of 2 to 3 soft stools daily rather than to a serum ammonia number alone.

Watery stool beyond the target is not extra efficacy; it raises dehydration and electrolyte risk and should trigger dose reassessment.

For lactulose in hepatic encephalopathy, the stool target guides dosing better than chasing ammonia.

Every class has a failure mode

The limitation is often more important than the mechanism diagram.

Bulk agents can worsen bloating and can obstruct when taken without enough fluid or in a patient with narrowing, dysphagia, impaction, or suspected mechanical obstruction.

Osmotic and stimulant drugs can cause diarrhea, dehydration, abdominal cramping, and electrolyte abnormalities; magnesium products deserve extra caution when renal clearance is impaired.

Lubiprostone commonly causes nausea, GC-C agonists can cause diarrhea, prucalopride can cause headache, nausea, abdominal pain, or diarrhea, and tenapanor can cause severe diarrhea and dehydration.

Secretagogues, prucalopride, and tenapanor should not be used through a known or suspected mechanical gastrointestinal obstruction, and severe diarrhea calls for stopping the causative drug and rehydrating.